Surmodics announces successful first patient use of Sublime radial access microcatheter

The Sublime microcatheter

Surmodics has announced that Ankur Lodha, MD, an interventional cardiologist at the Cardiovascular Institute of the South in Lafayette, Lousiana, and Pradeep Nair, director of the institute’s vein program, were the first physicians to use the company’s Sublime radial access microcatheter. 

The Sublime microcatheter is in limited market evaluation, a press release notes. The full suite of Sublime microcatheters will be launched in 2024. The Sublime portfolio will include the industry’s first suite of 0.014”, 0.018”, and 0.035” high-performance peripheral microcatheters.

“For peripheral as well as coronary interventions, radial access is safer than femoral access and much preferred by patients,” said Lodha. “I am pleased to report that the Sublime microcatheter performed exceptionally well during our first uses of the device in treating peripheral arterial disease [PAD].”

“The lack of long-length, high-performance catheters for peripheral procedures has slowed adoption of radial access for treatment of lower-extremity artery disease,” added Nair. “Sublime microcatheters will fill a major gap in the peripheral-intervention toolkit, including for procedures from access sites other than the wrist.”

Available in five lengths from 65 to 200cm and compatible with 0.014”, 0.018”, and 0.035” guidewires, the press release details that the Sublime microcatheters Surmodics’ Pristyne hydrophilic coating for lubricity to optimize device trackability through vessel tortuosity. The device’s dual stainless steel, locked-braid layers work in unison to optimize torque control, push transmission, and deliverability to distal target lesions, the company adds.

The microcatheters are available in straight or angled tip configurations. The Sublime 0.014” and 0.018” microcatheters can be telescoped through the 0.035” Sublime microcatheter to provide additional back up support when navigating extreme tortuosity or heavily stenosed lesions, the press release continues.


Please enter your comment!
Please enter your name here